Loading organizations...
Key people at Mindology.fr.
Mindology.fr develops and markets natural dietary supplements specifically formulated to alleviate symptoms associated with menopause. Its core offering utilizes phytotherapy, a plant-based medicinal approach, to address common issues such as insomnia, hot flashes, stress, and fatigue. The company emphasizes its collaboration with medical professionals in the product development process, ensuring scientifically informed solutions manufactured in France.
Mindology.fr was co-founded by Léa Philippot, though the specific founding date and the full context of the originating insight remain less publicly detailed. The venture likely stemmed from a recognition of unmet needs for effective, natural alternatives in managing menopausal transitions, aiming to empower women through this life stage with holistic, plant-derived care.
The company's primary customers are women seeking natural and gentle relief from menopausal discomforts. Mindology.fr is dedicated to providing accessible, high-quality phytotherapeutic options, fostering well-being and improved quality of life for its users. The long-term vision is centered on becoming a trusted partner for women navigating menopause, championing natural health solutions.
Key people at Mindology.fr.
Mindology.fr is a French wellness startup founded in 2021, offering a digital platform that combines phytotherapy, CBD, and guided programs as a natural alternative to benzodiazepines for managing anxiety and insomnia, particularly targeting women over 50 post-menopause to reduce risks of dementia and Alzheimer's.[1] The company serves women experiencing menopause-related mental health challenges, solving the problem of benzo dependency—which affects 1/3 of women post-menopause, with twice the Alzheimer's risk at age 70—through personalized digital diagnosis, natural supplements based on psychobiome research, and wellness products like CBD oils and French medicinal plants.[1][2][7] With a small team of about 5 employees in Paris and early funding from investors like Dimitri Farber Garcia, Thierry Roussel, and Alexandre Dana, Mindology shows initial traction in the natural health market but limited public data on growth metrics.[1][3]
Mindology was founded in 2021 in Boulogne-Billancourt, France, by Léa Philippot and Agathe Lecocq, both based in Paris.[1] Léa, the CEO, shares her personal journey with anxiety and insomnia on LinkedIn and is building sustainable mental health solutions; Agathe focuses on creating "love brands" and sustainable mental health alternatives.[1] The idea emerged from addressing the vulnerabilities of post-menopausal women to benzo-related cognitive risks, leveraging French phytotherapy and emerging psychobiome research to develop natural supplements and a digital platform for relief.[1][7] Early traction includes seed funding from three investors and a roadmap for personalized diagnosis tools, positioning it as a response to rising demand for non-pharmaceutical mental health options.[1]
(Note: Other "Mindology" entities in corporate training or psychotherapy appear unrelated based on location and focus.[3][4][5][6])
Mindology rides the global wellness tech and natural mental health wave, fueled by post-pandemic anxiety surges, menopause awareness, and skepticism toward pharmaceuticals amid benzo side-effect scrutiny.[1][7] Timing aligns with EU regulatory shifts favoring CBD/phytotherapy and digital health adoption in France's thriving startup scene (e.g., via platforms like F6S and Startup Luxembourg directories).[1][2] Market forces like aging populations, psychobiome research breakthroughs, and demand for personalized femtech solutions work in its favor, as women over 50 represent a growing, underserved segment in a $5T+ wellness industry. It influences the ecosystem by pioneering natural alternatives in sleep medicine and alternative health PaaS, potentially inspiring similar hybrid digital-natural platforms in Europe's healthtech space.[1]
Mindology is poised to scale its personalized diagnosis and guidance features, expanding from early funding to broader EU distribution of CBD/phytotherapy products amid rising femtech investment.[1] Trends like AI-driven mental health personalization, psychobiome advancements, and benzo backlash will shape its path, with potential for partnerships in France's wellness ecosystem. Its influence may evolve from niche startup to category leader if it achieves clinical validation and user growth, ultimately empowering more women with sustainable anxiety relief—reinforcing its mission as the go-to natural benzo alternative.[1][7]
